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Abstract 
Background: Alogliptin, a dipeptidyl-peptidase 4 inhibitor, is approved for the 
treatment of patients with type 2 diabetes. EXAMINE was a randomized-
controlled clinical trial designed to demonstrate the cardiovascular safety of 
alogliptin. In the trial, 5380 patients with established T2DM who had a recent 
ACS event (between 15-90 days) were randomized to treatment with either 
alogliptin or placebo.  
Hypothesis: To better understand and describe the cardiovascular (CV) safety 
of alogliptin, we analyzed data from the EXAMINE randomized clinical trial to 
determine whether treatment with alogliptin affected recurrent and total CV 
This article is protected by copyright. All rights reserved.
 
 
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which 
may lead to differences between this version and the Version of Record. Please cite this 
article as doi: 10.1111/clc.22960 
  
A
cc
ep
te
d
 A
rt
ic
le
events.  
Methods: Poisson regression analysis was performed to compare the total 
number of occurrences of CV death, MI, stroke, unstable angina, and coronary 
revascularization between all patients randomized to alogliptin versus placebo 
groups.  
Results: Patients with recurrent CV events were older and more likely to have 
renal disease and history of heart failure. There were 1100 first CV events and 
an additional 666 recurrent events over a median of 18 months of follow-up. 
There were no significant differences with regard to the total number of events in 
patients treated with alogliptin (n=873) or placebo (n=893; p=0.52). Furthermore, 
there were no differences in the types of events seen in patients treated with 
alogliptin or placebo. 
Conclusion: Alogliptin did not increase the risk of either first or recurrent CV 
events when compared to placebo in patients with type 2 diabetes and recent 
ACS. These data support the CV safety of alogliptin in patients who are at 
increased risk of future CV events.  
Word Count: 245 
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Alogliptin, a dipeptidyl-peptidase 4 inhibitor, is approved for the treatment of 
patients with type 2 diabetes (T2DM). The Examination of Cardiovascular 
Outcomes with Alogliptin versus Standard of Care (EXAMINE) study was a 
randomized, double-blind, placebo-controlled, multinational trial of alogliptin in 
patients with T2DM that were enrolled 15 to 90 days after an acute coronary 
syndrome (ACS). In the EXAMINE trial, there was neither an increase nor 
decrease in the risk of time to first CV death, MI, or stroke (MACE).(1) To better 
understand and describe the cardiovascular safety of alogliptin by providing a 
comprehensive picture of total CV events, we sought to determine the number of 
initial, recurrent and total CV events (CV death, MI, stroke, unstable angina and 
coronary revascularization) which occurred in the EXAMINE trial.  
Methods 
The full details of the EXAMINE trial have been previously published 
(clinicaltrials.gov: NCT00968708).(2) In brief, patients were eligible for the trial if 
they had established T2DM, were being treated with pharmacotherapies for 
T2DM (with the exception of a DPP-IV inhibitor or GLP-1 agonist), had a HbA1c 
level between 6.5% and 11.0% (7.0-10.0% if on insulin), and had a recent ACS 
event (either a myocardial infarction or unstable angina within 15-90 days of 
randomization). Patients with type 1 diabetes, end stage renal disease who had 
received hemodialysis within 14 days of screening, or unstable cardiovascular 
disorders (NYHA Class IV heart failure, refractory angina, uncontrolled 
arrhythmias, critical valvular heart disease, severe uncontrolled hypertension) 
were not eligible for the study.  
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 Eligible patients with T2DM and recent ACS were randomly assigned to 
treatment with either alogliptin or placebo. Patients with a GFR ≥60 milliliters per 
minute per 1.73 m2 of body surface area were treated with 25mg of alogliptin or 
matching placebo. Alogliptin is cleared via renal excretion so patients with a GFR 
of 30 to <60 milliliters per minute per 1.73 m2 of body surface area were treated 
with 12.5 mg of alogliptin/placebo and 6.25 mg of alogliptin/placebo was used in 
patients with a GFR <30 milliliters per minute per 1.73 m2 of body surface area.  
During the course of the trial, patients were to continue with evidence-based 
therapies for their T2DM and risk factors for cardiovascular disease prescribed 
by their health care providers. Hemoglobin A1c was not blinded during the study 
and clinicians were encouraged to treat patients based on regional guidelines; 
however, treatment with GLP-1 agonists or DPP-4 inhibitors during the course of 
the trial were prohibited. Treatment allocation was blinded to patients and 
investigators throughout the course of the study. National regulatory authorities 
and institutional ethics committees at each site approved the study design and all 
participants provided written informed consent.  
 The primary endpoint of the EXAMINE trial was the time to the first 
incidence of cardiovascular death, non-fatal myocardial infarction, or non-fatal 
stroke. For the purposes of this analysis in which we sought to better understand 
the total burden of cardiovascular events in patients with T2DM following a recent 
ACS, we evaluated a broader composite endpoint of cardiovascular death, non-
fatal myocardial infarction, non-fatal stroke, or coronary revascularization (either 
PCI or CABG). Heart failure has been the topic of a prior analysis and publication 
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and was not included in this analysis.(3) All clinical endpoints evaluated in the 
trial were adjudicated by a clinical events committee using prespecified 
definitions based on the guidelines from the Food and Drug Administration.(4) 
Fatal events were counted as a single event, such that, if a patient experienced 
an MI and then had CV death with the cause of death adjudicated as being due 
to the MI, the event was considered 1 fatal MI event. 
 Comparisons between baseline characteristics were made with the chi-
square test (categorical) and Kruskal-Wallis (continuous). Poisson regression 
analysis was performed to compare the total number of occurrences of CV death, 
MI, stroke, unstable angina, and coronary revascularization between all patients 
in the alogliptin and placebo groups. All statistical analyses were performed by 
independent academic statisticians using SAS Version 9.4 (Cary, NC) at the 
Baim Institute for Clinical Research (Boston, MA).  
Results 
Of the 5380 patients randomized in the EXAMINE trial following an ACS 
event, 1100 patients had at least one post-randomization cardiovascular event 
over a median follow-up period of 18 months (Table 1). Over this follow-up 
period, in the 1100 patients with a cardiovascular event during the trial, 380 
patients had an additional cardiovascular event (resulting in a total of 666 
recurrent cardiovascular events) (Table 1). The majority of patients randomized 
in the trial did not have an additional cardiovascular event (79.6%, n=4280) while 
13.4% (n=720) had a single recurrent cardiovascular event and 7.1% (n=380) 
had multiple recurrent cardiovascular events. Patients with recurrent CV events 
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were older, had type 2 diabetes for a longer duration, had higher prevalence of 
heart failure, peripheral arterial disease, prior stroke, and were more likely to 
have renal disease (Table 1). 
 In the patients who had multiple cardiovascular events during followup, the 
burden of recurrent events was high with the mean number of cardiovascular 
events being 1.6±1.2 events per patient (Table 2). There were a considerable 
number of patients who had multiple events including 12 patients who had ≥6 
events (Figure 1). In the 2701 patients treated with alogliptin, there were 545 
initial events and 328 recurrent events and in the 2679 patients treated with 
placebo there were 555 initial events and 338 recurrent events (Figure 2A). 
There was no difference in the number or type of cardiovascular events that 
occurred during followup in the alogliptin or placebo groups (p=0.52, Poisson) 
(Figure 2B).  
Predictors for multiple cardiovascular events included having myocardial 
infarction or revascularization prior to the index ACS that led to study entry.  
(Table 3).  
Discussion 
In this analysis of the EXAMINE trial, we found that the burden of 
cardiovascular events is high and recurrent events are common in patients with 
diabetes and recent ACS. While clinical effectiveness studies including both 
randomized controlled clinical trials and observational studies traditionally focus 
on the incidence of the first cardiovascular event, this underestimates the true 
burden of cardiovascular events since it does not take into account those 
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patients who have multiple recurrent events.(5, 6) Secondly, we found that those 
patients with recurrent events are at increased risk of mortality and the presence 
of known cardiovascular disease (prior MI or revascularization) identifies patients 
with diabetes in whom recurrent events are more common.(7) In those patients 
with these characteristics, intensive medical therapy and close clinical monitoring 
should be considered in an attempt to minimize the risk of future cardiovascular 
events and death. Importantly, alogliptin did not increase nor decrease the risk of 
initial or recurrent cardiovascular events in patients with diabetes even after 
accounting for all the initial and recurrent events which occurred during the study.  
During clinical trial follow-up, data on all cardiovascular events of interest 
are collected, although when performing comparative effectiveness analyses, the 
reporting is typically performed by analyzing only the first occurrence of a 
cardiovascular event. However, patients, clinicians, and payers have 
considerable interest in the total burden of cardiovascular events.(8, 9) Prior 
studies have found that intensive lipid control with high dose statins and more 
potent anti-platelet therapies can reduce the overall burden of cardiovascular 
events.(10, 11) These studies highlight the importance of assessing recurrent 
events to provide an overall picture of benefit.  
The EXAMINE trial was designed to demonstrate the cardiovascular 
safety of alogliptin, a DPP-4 inhibitor, as required by guidance from the United 
States Food and Drug Administration. (12) This current analysis of all ischemic 
cardiovascular events which occurred in the EXAMINE trial allows for a more 
complete assessment of the overall cardiovascular safety of alogliptin and 
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provides additional evidence supporting the safety of alogliptin for use in the 
treatment of patients with type 2 diabetes and cardiovascular disease. We found 
that 7.1% of the patients enrolled in the EXAMINE trial had multiple 
cardiovascular events following the initial ACS event. Prior studies have found 
that a small proportion of patients account for the majority of health care 
expenditures in the United States.(13) In the EXAMINE study, those patients with 
recurrent/multiple events were older, had diabetes for a prolonged period of time, 
or had heart failure or prior atherothrombotic disorders (peripheral arterial 
disease, stroke). Prior ischemic events with either a coronary revascularization or 
myocardial infarction were independent predictors of having multiple 
cardiovascular events in our population of patients with diabetes. Identification of 
patient characteristics associated with a higher likelihood of recurrent events over 
the short and intermediate term following an ACS are needed to allow for the 
development of strategies to identify these high risk patients. Prior efforts to 
identify patients who are high risk of readmission following a heart failure 
admission with intensification of followup and therapy have been successful in 
reducing readmission rates.(14) Thus, it is possible that the design of 
interventions to increase the intensity of therapies in patients with diabetes who 
are at high risk for additional events could have the potential to improve 
outcomes while minimizing costs and result in reduced overall healthcare costs.  
These data should be considered in the light of several potential 
limitations. First, the EXAMINE trial had a median followup time of 18 months 
which is relatively short given the duration of time in which patients live with 
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diabetes. Thus, it is possible that differences between therapies could emerge 
over a longer followup period. Secondly, in this analysis we did not assess 
events such as total hospitalizations, serious adverse events or total health care 
expenditures which are also important when considering the overall burden 
related to diabetes. Finally, there could be differences between patients who died 
and were censored because of the occurrence of a fatal event or concomitant 
treatments among patients who experienced a nonfatal event during the trial; 
however, we found no overall differences in the total number of cardiovascular 
events, including death, in patients treated with alogliptin or placebo, making this 
concern unlikely to be relevant.  
In conclusion, patients with diabetes and recent ACS commonly have high 
burdens of recurrent events and these events seem to concentrated in a minority 
of patients. Alogliptin did not increase nor decrease the risk of either first or 
recurrent cardiovascular events when compared to placebo in patients with 
T2DM and recent ACS.  These data support the CV safety of alogliptin in patients 
with diabetes and increased risk of future CV events. Further studies are needed 
to identify pharmacotherapies and interventions that can reduce the continued 
burden of cardiovascular disease in high risk populations of patients with 
diabetes and ACS.  
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Table 1 – Baseline Characteristics stratified by number of post-randomization 
cardiovascular events. 
 
Characteristics 
No Event 
(N=4280) 
1 Event 
(N=720) 
Multiple Events 
(N=380) p-value 
Alogliptin 50.4% (2156/4280) 48.6% (350/720) 51.3% (195/380) 0.62 
Age; Median (Q1,Q3) 60 (54,68) 62 (55,70) 62 (55,68) <0.001 
Male 68.4% (2926/4280) 66.3% (477/720) 65.3% (248/380) 0.28 
Duration of diabetes (years); Median 
(Q1,Q3) 
6.7 (2.5,13.0) 9.2 (3.5,15.3) 9.9 (4.8,16.2) <0.001 
Baseline HbA1c concentration; Median 
(Q1,Q3) 
7.9 (7.2,8.7) 7.9 (7.2,8.7) 8.0 (7.3,8.8) 0.42 
BMI (kg/m2); Median (Q1,Q3) 28.7 (25.6,32.4) 28.7 (25.3,32.8) 29.3 (26.0,33.8) 0.01 
Race    <0.001 
    American Indian or Alaska Native 2.1% (91/4280) 2.2% (16/720) 0.8% (3/380)  
    Asian 20.4% (872/4280) 23.1% (166/720) 13.4% (51/380)  
    Black or African American 3.6% (153/4280) 5.8% (42/720) 5.5% (21/380)  
    Native Hawaiian or Other Pacific 
Islander 
0.2% (10/4280) 0.1% (1/720) 0.0% (0/380)  
    White 72.8% (3116/4280) 67.9% (489/720) 80.0% (304/380)  
    Multiracial 0.9% (38/4280) 0.8% (6/720) 0.3% (1/380)  
Region of world    <0.001 
    United States, Canada 15.1% (647/4280) 16.3% (117/720) 23.4% (89/380)  
    Western Europe, Australia, New 
Zealand and Middle East 
10.9% (467/4280) 11.1% (80/720) 18.2% (69/380)  
    Central and South America, Mexico 26.7% (1141/4280) 24.4% (176/720) 20.0% (76/380)  
    Eastern Europe and Africa 28.4% (1216/4280) 26.8% (193/720) 26.1% (99/380)  
    Asia, Pacific Islands 18.9% (809/4280) 21.4% (154/720) 12.4% (47/380)  
Cardiovascular Risk Factors and History     
    Current smoker 13.8% (592/4280) 12.5% (90/720) 13.7% (52/380) 0.32 
    Hypertension 81.4% (3484/4280) 89.2% (642/720) 90.3% (343/380) <0.001 
    Myocardial infarction* 0.0% (0/4280) 19.0% (137/720) 59.7% (227/380) <0.001 
    PCI* 0.0% (0/4280) 28.6% (206/720) 66.6% (253/380) <0.001 
    CABG* 0.0% (0/4280) 8.1% (58/720) 15.3% (58/380) <0.001 
    Congestive Heart Failure 26.6% (1137/4280) 34.9% (251/720) 29.7% (113/380) <0.001 
    Cerebrovascular Accident 6.1% (262/4280) 12.1% (87/720) 10.3% (39/380) <0.001 
    Peripheral Arterial Disease 8.6% (369/4280) 11.7% (84/720) 16.1% (61/380) <0.001 
Renal function eGFR (mL/min/1.73 m2)     
    Mean±SD (N) 72.0±21.0 (4280) 65.9±22.1 (720) 68.1±22.7 (380) <0.001 
    Median (Q1,Q3) 72.4 (58.1,86.1) 65.8 (50.7,80.8) 67.3 (53.2,84.7)  
    Range (min,max) (4.2,186.1) (5.0,136.1) (13.7,169.6)  
    eGFR < 60 mL/min/1.73 m2 27.0% (1157/4280) 39.7% (286/720) 32.1% (122/380) <0.001 
    eGFR >= 60 mL/min/1.73 m2 73.0% (3123/4280) 60.3% (434/720) 67.9% (258/380)  
Index ACS event    0.07 
    Myocardial infarction 76.7% (3273/4267) 79.7% (574/720) 80.5% (305/379)  
    Unstable angina 23.3% (994/4267) 20.3% (146/720) 19.5% (74/379)  
Time from index ACS event to 
randomization (days) 
    
    Mean±SD (N) 48.5±22.1 (4267) 45.5±21.5 (720) 44.2±21.2 (379) <0.001 
    Median (Q1,Q3) 45.0 (30.0,65.0) 41.0 (28.0,61.0) 41.0 (27.0,59.0)  
    Range (min,max) (8.0,141.0) (10.0,97.0) (10.0,101.0)  
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Table 2 – Number of events per patient with alogliptin or placebo during followup 
of the EXAMINE trial. 
 
Endpoints Alogliptin (N=2701) Placebo (N=2679) p-value Total (N=5380) 
Number of events per 
patient 
    
    Mean±SD (N) 1.6±1.1 (545) 1.6±1.2 (555) 0.54 1.6±1.2 (1100) 
    Median (Q1,Q3) 1.0 (1.0, 2.0) 1.0 (1.0, 2.0)  1.0 (1.0, 2.0) 
    Range (min,max) (1.0, 11.0) (1.0, 14.0)  (1.0, 14.0) 
CV Death 4.1% (112/2701) 4.9% (130/2679) 0.21 4.5% (242/5380) 
Death 5.7% (153/2701) 6.5% (173/2679) 0.223 6.1% (326/5380) 
Number of non-fatal events 
per patient 
    
    Mean±SD (N) 1.6±1.1 (462) 1.7±1.3 (449) 0.91 1.7±1.2 (911) 
    Median (Q1,Q3) 1.0 (1.0, 2.0) 1.0 (1.0, 2.0)  1.0 (1.0, 2.0) 
    Range (min,max) (1.0, 11.0) (1.0, 14.0)  (1.0, 14.0) 
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Table 3 – Predictors of recurrent cardiovascular events in patients with diabetes.  
Predictors 
Odds Ratio 
[95% CI] P-value 
Central and South America, Mexico (as compared 
to United States/Canada) 
1.04 [0.76-1.43] 0.81 
Western Europe, Australia, New Zealand and 
Middle East (as compared to United 
States/Canada) 
1.26 [0.89-1.79] 0.19 
Eastern Europe and Africa (as compared to 
United States/Canada) 
0.86 [0.63-1.16] 0.31 
Asia, Pacific Islands (as compared to United 
States/Canada) 
0.62 [0.44-0.88] 0.01 
Myocardial Infarction* 119.72 [72.49- 197.72] <0.001 
PCI* 138.79 [85.69- 224.80] <0.001 
CABG* 80.58 [41.52- 156.39] <0.001 
* Prior to randomization and before the index ACS 
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